Becton, Dickinson and Company $BDX Stake Increased by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,112,958 shares of the medical instruments supplier’s stock after buying an additional 5,109 shares during the quarter. Becton, Dickinson and Company accounts for 1.0% of Fort Washington Investment Advisors Inc. OH’s portfolio, making the stock its 23rd largest position. Fort Washington Investment Advisors Inc. OH owned about 0.40% of Becton, Dickinson and Company worth $199,672,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Brown Lisle Cummings Inc. lifted its stake in shares of Becton, Dickinson and Company by 9.2% during the second quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier’s stock worth $97,000 after purchasing an additional 54 shares in the last quarter. Elevation Point Wealth Partners LLC raised its holdings in shares of Becton, Dickinson and Company by 3.7% during the 2nd quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock valued at $256,000 after buying an additional 60 shares during the period. Private Harbour Investment Management & Counsel LLC raised its holdings in shares of Becton, Dickinson and Company by 1.1% during the 2nd quarter. Private Harbour Investment Management & Counsel LLC now owns 5,511 shares of the medical instruments supplier’s stock valued at $834,000 after buying an additional 62 shares during the period. NorthRock Partners LLC raised its holdings in shares of Becton, Dickinson and Company by 2.0% during the 2nd quarter. NorthRock Partners LLC now owns 3,295 shares of the medical instruments supplier’s stock valued at $499,000 after buying an additional 65 shares during the period. Finally, QRG Capital Management Inc. lifted its position in Becton, Dickinson and Company by 0.7% during the 2nd quarter. QRG Capital Management Inc. now owns 8,798 shares of the medical instruments supplier’s stock worth $1,331,000 after acquiring an additional 65 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Thomas Polen, Jr. sold 4,152 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the completion of the transaction, the chief executive officer owned 110,163 shares in the company, valued at $20,380,155. The trade was a 3.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of the company’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the transaction, the executive vice president owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 6,906 shares of company stock valued at $1,265,855. Company insiders own 0.40% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on BDX. Weiss Ratings upgraded Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 28th. Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. Jefferies Financial Group reissued a “buy” rating and issued a $210.00 price target on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Royal Bank Of Canada raised their price objective on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research note on Thursday, August 13th. Finally, Barclays began coverage on Becton, Dickinson and Company in a report on Wednesday, October 7th. They set an “underweight” rating and a $165.00 price objective on the stock. Seven research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $185.07.

Becton, Dickinson and Company Stock Performance

BDX stock opened at $188.83 on Thursday. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The firm has a market cap of $52.03 billion, a P/E ratio of 14.41, a P/E/G ratio of 12.63 and a beta of 0.21. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $193.07. The stock’s 50 day simple moving average is $183.41 and its 200 day simple moving average is $163.23.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The firm had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period last year, the business posted $3.68 earnings per share. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date was Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 126.51%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD’s Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.